Biomarker Research in Parkinson's Disease Using Metabolite Profiling

Area of Science:

• Neuroscience
• Biochemistry
• Biomarker Discovery

Background:

• Current Parkinson's disease (PD) biomarkers like dopamine metabolites lack sensitivity for early detection and monitoring.
• PD is increasingly recognized as a multifactorial condition necessitating precise diagnostics and personalized treatment strategies.

Purpose of the Study:

• To review the application of metabolomics in identifying novel biomarkers for Parkinson's disease.
• To explore metabolic fingerprints in various body fluids for PD diagnosis and prognosis.
• To understand the role of metabolic alterations in PD pathophysiology.

Main Methods:

• Review of clinical and experimental studies utilizing metabolite profiling (metabolomics) in Parkinson's disease.
• Analysis of various analytical platforms and methodologies for body fluid analysis (serum/plasma, CSF, urine).
• Discussion of identified metabolic pathways and potential biomarker utility.

Main Results:

• Metabolomics reveals characteristic "metabolic fingerprints" for PD across different disease stages.
• Consistent alterations observed in alanine, branched-chain amino acid, and fatty acid metabolism, suggesting mitochondrial dysfunction.
• Changes in aromatic amino acid and purine metabolism (e.g., uric acid) are frequently reported in PD metabolite profiling studies.

Conclusions:

• Metabolomics represents a powerful tool for discovering novel, sensitive biomarkers in Parkinson's disease.
• Metabolic profiling provides insights into the multifactorial nature and pathophysiology of PD, particularly mitochondrial dysfunction.
• These findings support the potential for improved diagnosis, prognosis, and personalized medicine in Parkinson's disease.